Login to Your Account

Pharma: Clinic Roundup

Tuesday, April 3, 2012

• ViiV Healthcare, of Brentford, UK, and Shionogi & Co. Ltd., of Osaka, Japan, said initial results indicated that once-daily dolutegravir, an integrase inhibitor, demonstrated noninferiority to twice-daily raltegravir in the SPRING-2 study in treatment-naïve HIV-1 patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription